Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDX-1203 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| MDX-1203 | EXPERIMENTAL | Accelerated titration design (ATD)of 6 dose levels. Subjects will be assigned to a dose level in the order they enter the study |
| Name | Type | Description |
|---|---|---|
| MDX-1203 | BIOLOGICAL | Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 * Criteria specific to each tumor type: * For Clear cell renal cell carcinoma (ccRCC): advanced or recurrent disease. Must have failed at least 1 prior systemic therapy * For B-cell non-Hodgkin's lymph...
MDX-1203 was studied for the treatment of advanced or recurrent clear cell renal cell carcinoma and relapsed or refractory B-cell non-Hodgkin's lymphoma. It is an oncology drug candidate that was evaluated in a single Phase 1 clinical trial. It is not an approved therapy.
MDX-1203 was developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the drug in renal cell carcinoma and non-Hodgkin's lymphoma.
MDX-1203 is in Phase 1 development. It has been evaluated in one completed Phase 1 clinical trial that enrolled 46 participants. The trial was uncontrolled, non-randomized, and not double-blinded. No active trials of MDX-1203 are currently listed.
MDX-1203 was studied in the Phase 1 trial NCT00944905, titled Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). The trial was conducted in the United States, enrolled 46 participants aged 18 years and older, and has been completed.
MDX-1203 is not approved by the FDA. It is an investigational monoclonal antibody that has completed a single Phase 1 clinical trial in renal cell carcinoma and non-Hodgkin's lymphoma. No regulatory approval has been granted for this drug candidate.
Yes, the Phase 1 trial of MDX-1203, NCT00944905, was biomarker-selected, meaning participants were enrolled based on specific biomarker criteria. The study evaluated the drug in adults with advanced or recurrent clear cell renal cell carcinoma or relapsed or refractory B-cell non-Hodgkin's lymphoma.